Eckert & Ziegler Q3/2012: Sales and Earnings in line. Increases in Earnings confirmed for 2013.
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results
06.11.2012 / 07:50
---------------------------------------------------------------------
Berlin, 6 November 2012. For Eckert & Ziegler AG, one of the leading manufacturers of isotope products for medicine, science and industry (ISIN DE0005659700), the first nine months of 2012 continued to be successful. Compared with the same period for the previous year, sales rose by 5% to 88 million EUR. Profit after taxes and minority interests achieved 7.1 million EUR or 1.34 EUR per share. This was therefore approx. 1.7 million EUR or 0.34 EUR per share below the value for the previous year. The main cause for this are the extraordinary expenses for the acquisition and incorporation of Eckert Ziegler Vitalea Inc., as well as the cost of aborting a very far advanced acquisition project, which was rejected after extensive examination. For the financial year 2012, the forecast profit remains unchanged at 1.95 EUR per share. A 20% increase in earnings to approx. 2.35 EUR per share is still expected for 2013.
The Isotope Products segment made the largest contribution to the overall result of the third quarter. Here sales revenues with external customers rose slightly by 1% to EUR 41.5 million. The aforementioned advantageous change in the exchange rate was the strongest in this segment, so that sales revenues remained constant - to somewhat simplify. Production and sales costs developed in proportion to sales revenues. However, administrative costs increased slightly, so that EBIT for the segment declined by EUR 0.4 million or 3% to EUR 12.6 million.
The Radiation Therapy segment posted exceptionally high sales figures for the new MultiSource(R) cancer radiation device in the third quarter. During the nine-month period, sales revenues rose by 12% to EUR 21.8 million. Due to changes in the product mix production costs increased more sharply than sales revenues, while sales costs declined slightly after the successful market launch. Overall, EBIT remained constant at EUR 1.9 million compared to the same period the previous year. Extensive information on the Radiation Therapy segment can also be found in Eckert & Ziegler BEBIG s.a. quarterly report, which is being published simultaneously (www.bebig.eu).
The Radiopharma segment has continued to grow at a moderate rate. Sales revenues increased by 4% to EUR 19.9, which is mainly due to the basis effect from the Bioscan acquisition in mid-2011. As compared to the same period of the previous year, expenditures for production and sales increased. Therefore, EBIT declined by 31% to EUR 2.2 million.
The strongest growth was posted by the Environmental Services segment. Sales revenues from external customers rose by 13% to EUR 4.6 million. As in the second quarter, provisions for the removal of old waste were also adjusted in the third quarter. This resulted in extraordinary expenditures, such that EBIT now shows a loss of EUR -1.3 million.
To read the full quarterly report please click here: http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl isch/euz312e.pdf
The Group anticipates sales revenues of about EUR 117 million and results of about EUR 10 million after taxes and minority interests in fiscal year 2012. For 2013, the budget plan, which has already been completed, projects a significant increase in sales revenues to EUR 125 million and an even higher increase in results after taxes and minority interests to EUR 12 million, provided that the average annual Euro/US dollar exchange rate does not rise above the current level of 1.30 USD per EUR.
With more than 600 employees the Eckert & Ziegler Group belongs to the largest providers of isotope components for radiotherapy and nuclear medicine worldwide.
If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
06.11.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
--------------------------------------------------------------------- 191559 06.11.2012